Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PST-809
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : PulseSight Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
PulseSight Launches to Advance Non-Viral Gene Therapies for Severe Retinal Diseases
Details : PST-809, is a potential first-in-class therapy for wet age-related macular degeneration that comprises a dual-gene plasmid encoding for anti-VEGF, aflibercept, together with decorin.
Brand Name : PST-809
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
February 27, 2024
Lead Product(s) : PST-809
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : PulseSight Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : T-cell Receptor Therapeutic
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Engimmune Therapeutics
Deal Size : $16.7 million
Deal Type : Financing
Details : Proceeds from the financing will be used to further build Engimmune’s pipeline having T-cell receptor based therapies, expand the research team in Switzerland, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 03, 2022
Lead Product(s) : T-cell Receptor Therapeutic
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Engimmune Therapeutics
Deal Size : $16.7 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?
Reset All
